The use of cannabis for the management of a wide range of painful disorders has been well documented in case reports throughout history. However, clinical evaluations of cannabis and its psychoactive constituent THC have not led to a consensus regarding their analgesic effectiveness. On the other hand, THC and its synthetic derivatives have been shown to be effective in most animal models of pain. These antinociceptive effects are mediated through cannabinoid receptors in the brain that in turn appear to interact with noradrenergic and kappa opioid systems in the spinal cord to modulate the perception of painful stimuli. The endogenous ligand, anandamide, is also an effective antinociceptive agent. The extent to which the endogenous cannabinoid system is involved in the modulation of pain is currently unknown.
INTRODUCTION
Cannabis has been promoted as a potential analgesic for several centuries. The introduction of cannabis into Western medicine has been attributed to a British army physician serving in India who noted its analgesic properties (1). Others reported on the use of cannabis for the treatment of psychiatric illnesses, insomnia, and appetite enhancement without causing physical addiction. It was also tried as a treatment for opium addiction, chronic alcoholism, delirium tremens, and a large variety of painful disorders. The U.S. Pharmacopoeia in the late 1890s described cannabis extracts as treatments for neuralgia, gout, rheumatism, tetanus, hydrophobia, epidemic cholera, convulsions, chorea, hysteria, mental depression, delirium tremens, insanity, and uterine hemorrhage. Interest in cannabis as a medicinal agent waned in the United States with the passage of the Marijuana Tax Act in the 1930s which made marijuana illegal. However, as recreational use of cannabis rose to prominence in the 1960s, the medical issues of cannabis followed soon thereafter.
Interest in cannabis, as well as synthetic analogs, for the possible management of pain remains high for several reasons. Advocates for the medical use of cannabis argue that this psychoative material is capable of controlling pain that is refractory to other analgesics. Additionally, a synthetic cannabinoid would most likely control pain by a novel mechanism thereby providing the possibility of developing a truly new class of analgesics. The realization that an endogenous cannabinoid system exists has provided the impetus for establishing its role in the modulation of pain. Other reviews of cannabinoid-induced analgesia have appeared (2). The objective of this review is to summarize the analgesic properties of cannabis, ⌬ 9 -THC, and its synthetic derivatives in humans and animals and to describe the mechanisms by which these agents produce these effects.
Before attempting to discuss the mechanism by which a class of compounds produces analgesia, it is important to understand pain, or nociception, itself. The perception of a noxious stimulus is a complex sensory phenomenon that is dependent upon a variety of factors including the type and intensity of the stimulus as well as which pain pathways are activated. The concept of nociception has been classified as either acute or chronic (3). Acute nociception has been further subdivided into phasic and tonic components (4). Whereas phasic noxious stimuli elicit withdrawal responses that are often reflexive and involve sensory or discriminatory processes, tonic nociception involves affective, motivation processes and typically elicits an integrated response. Phasic nociceptive responses occur to a sharp, sudden, transient noxious stimulus and occurs as long as the noxious stimulus stimulates nociceptors. Examples of nociceptive tests that assess phasic nociception in laboratory animals include the tail-flick, paw pressure, hot plate, and tooth pulp tests. Tonic nociception is often caused by tissue damage; is
